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Summary
Objective: The S0/S0 (S/S, S/Lg and Lg/Lg) variant of the serotonin (5-HT) transporter gene linked
polymorphic region (5-HTTLPR) is associated with less efficient neurotransmission and may be
more reactive to 5-HT manipulations. We tested the effects of L-tryptophan supplements on the
cortisol response induced by a social stressor in S0/S0 and L0/L0 (La/La) carriers.
Methods: In a double-blind parallel design, 25 S0/S0 carriers and 21 L0/L0 carriers were randomised
to take L-tryptophan (2.8 g/d) or placebo supplements for six days. At day 7 participants were
exposed to the Trier Social Stress Test. Salivary cortisol and subjective mood states were
monitored before, during and after the stress procedure.
Results: S0/S0 carriers who took L-tryptophan supplements had a significantly lower cortisol
response to stress than S0/S0 carriers who took placebo. Tryptophan had no effect on cortisol in L0/
L0 carriers and no effect on subjective mood states in either genotype group.
Conclusion: Tryptophan attenuates the cortisol response to acute social stress depending on 5-
HTTLPR genotype. S0/S0 carriers may indeed be more reactive to 5-HT manipulations.
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The serotonin (5-hydroxytryptamine; 5-HT) neurotransmis-
sion system and the hypothalamic—pituitary—adrenal axis
(HPA axis) have complex interrelationships (Porter et al.,
2004). Both systems have important roles in the response to* Corresponding author at: Leiden University, Institute of Psychol-
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Open access under the Elsevier OA license.stress and are implicated in depression. In the present study,
we examined the effect of the 5-HT precursor L-tryptophan
(TRP) on reactivity of the HPA axis, specifically investigating
whether this effect is modulated by genetic variation in the
5-HT system.
The serotonin transporter (5-HTT) membrane protein is
essential in regulating the concentration of 5-HT in the
synaptic cleft. The 5-HTT is encoded by the SLC6A4 gene,
and transcriptional activity of this gene is regulated by the 5-
HTT-linked polymorphic region (5-HTTLPR). Two major var-
iants of the 5-HTTLPR exist, with functional significance in
that the short (S) allele of the 5-HTTLPR is associated with
less transcriptional efficiency and less 5-HTT expression than
202 H. Cerit et al.is the long (L) allele (Lesch et al., 1996). A functional A/G
polymorphism (rs25531) has been found within the L allele
(Nakamura et al., 2000) as well, indicating that the 5-
HTTLPR is functionally triallelic (S/Lg/La). The Lg variant
is associated with reduced 5-HTT transcriptional efficiency,
comparable to the S allele (Hu et al., 2006; Praschak-Rieder
et al., 2007; Reimold et al., 2006). The reduced efficiency 5-
HTT variants (S and Lg) are referred to as S0, the La variant as
L0. Biallelic classifications are indicated as S and L.
Several studies have found that differences in 5-HTTLPR
genotype are associated with differing HPA axis reactivity in
healthy individuals. Healthy girls (aged between 9 and 14
years) who were homozygous for the S allele showed an
increase in cortisol response during and following exposure
to a laboratory stress task, whereas girls carrying at least one
copy of the L allele had a slight decrease in cortisol response
(Gotlib et al., 2008). This differential pattern of cortisol
response was independent from history of depression in
participants’ mothers. Way and Taylor (2010) exposed
healthy young adults to a similar social stress task and found
that individuals homozygous for the S allele had a signifi-
cantly stronger cortisol response 40 min after onset of the
stressor. The individuals homozygous for the L allele had the
least response, with the heterozygous (S/L) falling in
between.
Wu¨st et al. (2009), however, did not observe an effect of 5-
HTTLPR on the cortisol response to a social stress task. This
study had a large sample size (N = 216) and grouped indivi-
duals based on triallelic classification. The non-replication
may have been caused by the fact that all 126 female
participants used oral contraceptives, which dampen the
cortisol response to stress (Kirschbaum et al., 1999). Another
recent study reported no effect of 5-HTTLPR genotype or
neuroticism on the cortisol response to social stress in 94
college students (Verschoor and Markus, 2011). Mueller et al.
(2011) even reported a larger cortisol response to social
stress in both younger (18—31 years) and older (54—68 years)
adults who were homozygous for the L0 allele than individuals
carrying at least one S0 allele. This effect was not observed in
children (8—12 years). In the younger adults (N = 106), gen-
otype interacted with early (during the first five years of life)
stressful life events: L0/L0 individuals had a much higher
cortisol response to stress than S0 carriers in the absence
of early stressful life events. This pattern was reversed for
people who had experienced three or more early life events.
In a study with newborns, S0/S0 individuals had a larger
cortisol response to a pain stimulus (heel prick) (Mueller
et al., 2010). Finally, male S0/S0 carriers with a history of
stressful life events had a larger cortisol response 35 min
after the onset of the social stressor than male S0/S0 carriers
without such history. The cortisol response in S0/S0 carriers
with a history of stressful life events was also higher than that
of male S0/L0 and L0/L0 carriers (with and without life events)
(Alexander et al., 2009).
The central theme of these reports demonstrates that 5-
HT function and 5-HTTLPR genotype affect HPA axis reac-
tivity to social stress; however, the direction of this inter-
action has yet to be conclusively established. Age as well as
both type and time of occurrence of stressful life events
have been suggested to play a role in the effect of gene—
environment interactions on cortisol response (Mueller
et al., 2011).The relationship between the 5-HT system and HPA axis
reactivity has also been investigated by manipulating tryp-
tophan (TRP) levels in stress-vulnerable populations, as
defined by family or personal history of depression or by
questionnaire scores indicating vulnerability, e.g. high neu-
roticism. Experimental interventions that temporarily
increase TRP include: carbohydrate rich/protein poor (CR/
PP) meal (Markus et al., 1998, 2000b), tryptophan-rich egg
protein hydrolysate (EPH) (Markus et al., 2010), carbohy-
drate rich drink (Markus, 2007), whey protein a-lactalbumin
(a-lac) (Markus et al., 2000a; Merens et al., 2005; Booij
et al., 2006; Nesic and Duka, 2008) and tryptophan-rich
hydrolysed protein (HP) (Firk and Markus, 2009). Stress
responses were induced with the cold pressor test (CPT),
arithmetic stress task (under noise stimulation) or public
speaking. Stress-vulnerable populations were expected to
benefit from increasing TRP availability, as expressed in
improved mood and lower cortisol responses to stress. The
above-mentioned interventions and stressors revealed no
consistent pattern of effects. The lack of a consistent effect
may have been due to methodological limitations, including:
a relatively small impact of the interventions on tryptophan
concentrations, less than optimal timing of the cortisol
measurements, or the nature of the stressor. Non-social
stressors (e.g. cold pressor) are less reliable in eliciting a
cortisol response than are social stressors (e.g. public speak-
ing) (Dickerson and Kemeny, 2004).
A recent study combined a TRP manipulation and stress
exposure with measurement of 5-HTTLPR genotype (Markus
and Firk, 2009). Sixteen healthy S0/S0 and 14 L0/L0 carriers
were exposed to stress 1 h after a single dose tryptophan
(0.8 g) and after taking placebo in a cross-over design. The
stress procedure consisted of a combination of backward
counting tasks and cold-pressor exposures at unpredictable
intervals. TRP improved mood and reduced backward count-
ing errors in S0/S0 participants but not in L0/L0 participants,
and no group differences were found on the cortisol response
to stress. Remarkably, cortisol concentrations were lower at
post-stress than at pre-stress regardless of intervention or
genotype. The number of cortisol measurements was limited
to single pre- and post-stress samplings. The authors con-
cluded that TRP challenge improves mood and stress perfor-
mance in S0/S0 participants (Markus and Firk, 2009). ‘Stress
performance’ referred to the number of errors in the back-
ward counting task that was part of the stressor. Under
placebo conditions, S0/S0 participants made more mistakes
than L0/L0 participants, which seems to have been corrected
by TRP.
Given the methodological issues in previous TRP loading
studies, we examined the effect of six days of TRP supple-
mentation on reactivity of the HPA axis to a social stressor,
specifically investigating whether its role is modulated by 5-
HTTLPR genotype. We used a parallel design, exposing every
participant to the stressor only once. Furthermore, we mon-
itored physiological data for 95 min at six time points pre-
and post-stress. Possible confounders of the stress response
were avoided by excluding users of oral contraceptives and
by testing female participants during the luteal phase of their
menstrual cycle. We tested the following hypotheses: (1) S0/
S0 carriers have larger cortisol responses to social stress than
L0/L0 carriers; (2) the increased cortisol response to stress of
S0/S0 carriers will be reduced by tryptophan.
Tryptophan, stress and serotonin transporter gene 2032. Methods and materials
2.1. Participants
Participants were selected from a pool of 581 genotyped
individuals who had been recruited at various sites at
Leiden University and through local advertisements. Par-
ticipants were non-smokers and were included if all four
grandparents were West-European. For the present study,
the age range was 18—35 years and Body Mass Index was
between 19 and 29 kg/m2). Exclusion criteria were a cur-
rent diagnosis of depression or post-traumatic stress dis-
order, a lifetime history of psychosis, and use of
medication, including oral contraceptives. The presence
of anxiety disorders was also assessed, but this was not an
exclusion criterion. The following two genotype groups S0/
S0 (S/S, S/Lg and Lg/Lg variants) and L0/L0 (La/La variant)
were invited to participate in the present study. Partici-
pants received a reward of s40. The research was
approved by the Ethics Committee of the Leiden University
Medical Center in The Netherlands.
2.2. Genotyping
2.2.1. Genetic assessment
DNA was obtained using the Oragene Self-Collection Kit —
DISC format (DNA Genotek Inc., Ottawa, ON, Canada); 200 ml
of saliva was collected in lysis buffer (100 mM NaCl, 10 mM
EDTA, 10 mM Tris pH 8, 0.1 mg/ml proteinase K and 0.5%, w/
v, SDS) until further processing. Genomic DNA was isolated
from the samples using the Chemagic buccal swab kit on a
Chemagen Module I workstation (Chemagen Biopolymer-
Technologie AG, Baesweiler, Germany). DNA concentrations
were quantified by OD260 measurement and by agarose gel
electrophoresis. The average yield was approximately 4 mg of
genomic DNA per sample.
2.3. Polymerase chain reaction amplification
The region of interest from the 5-HTT gene was amplified by
triplex PCR using the following primers: a FAM-labelled pri-
mer HTTLPR-FWFAM 50-TCCTCCGCTTTGGCGCCTCTTCC-30,
and a reverse primer HTTLPR-RV 50-TGGGGGTTGCAGGGGA-
GATCCTG-30. Typical PCR reactions contained between 10
and 100 ng genomic DNA template, 10 pmol of forward and
reverse primer. PCR was carried out in the presence of 5%
DMSO with 0.5 U of BioThermAB polymerase (GeneCraft,
Munster, Germany) in a total volume of 30 ml using the
following cycling conditions: initial denaturation step of
5 min at 95 8C, followed by 40 cycles of 30 s 96 8C, 30 s
61 8C, 60 s 72 8C and a final extension step of 10 min 72 8C.
After PCR 5 ml of the sample was subjected to restriction
digestion with the enzyme HpaII in a total volume of 20 ml.
Restriction enzyme mix was incubated with DNA for 3 h at
37 8C.
2.4. Analysis of PCR products
One microlitre of PCR product before and after restriction
digestion was mixed with LIZ-500 size standard and forma-
mide and run in two separate lanes on an AB 3100 geneticanalyser set up for genotyping with 50 cm capillaries. Results
were analysed using Genescan software version 3.7 (Applied
Biosystems, Carlsbad, CA, USA), and alleles were scored
visually according to the following scheme: Uncut: S,
469 bp; L, 512 bp. Cut: Sg, 402 + 67 bp; Lg, 402 + 110 bp.
2.5. Instruments
2.5.1. Diagnosis
The Mini International Neuropsychiatric Interview (M.I.N.I.)
was administered (Sheehan et al., 1997; Van Vliet et al.,
2000) to assess psychiatric diagnoses.
2.5.2. Psychiatric symptoms and mood states
Three self-report questionnaires were used. Current symp-
toms of anxiety and depression were measured using the
hospital anxiety and depression scale (HADS; Zigmond and
Snaith, 1983; Spinhoven et al., 1997). The HADS is a 14-item
self-report scale which assesses past-week severity of anxi-
ety and depressive symptoms. Positive and negative affect
was assessed by means of the Positive and Negative Affec-
tivity Scales (PANAS), a 20-item questionnaire (Watson et al.,
1988). The state version (today) was used. The mood states
Sadness, Annoyance, Tension and Anxiety were assessed using
single-item Mood States Scales (MSS) with scores ranging from
0 (not at all) to 10 (extremely).
2.6. Stress induction
The Trier Social Stress Test (TSST; Kirschbaum et al., 1993)
is a combination of a public speaking task in front of an
unresponsive audience and a mental arithmetic task at
high speed and with public correction of every mistake.
During an initial resting period of 50 min, baseline saliva
cortisol samples were obtained at time points t15 and t50.
Subsequently, participants were informed that they were
about to give a speech in front of an audience consisting of
three persons, and that they would also complete another
task that this audience would announce to them (i.e. the
mental arithmetic task). The TSST protocol further pre-
scribes that participants were informed that their speech
would be videotaped and evaluated by skilled psychologists
with regard to content and performance. During the verbal
instructions the experimenter briefly showed the room
with the audience waiting for him/her. Subsequently, par-
ticipants were placed in a quiet room and given 6 min to
prepare themselves. They were instructed that it was not
allowed to keep any notes during their speech. At the end
of this anticipation period, another saliva sample was
taken and the participant entered the room in order to
deliver the speech and complete the arithmetic task. At
the end of the arithmetic task, the experimenter entered
the room and took another saliva sample in front of the
audience. Subsequently, the participant was guided to a
quiet room and was allowed to rest and read magazines for
45 min. Saliva samples were collected at six points in time
(with t0 representing the time of arrival): rest 1 (t15), rest
2 (t50), after anticipation (t56), after speech and arith-
metic task (t65) and twice during the recovery period (t90
and t110). During saliva sampling participants rated their
mood states on the MSS.
Table 1 Demographic characteristics for both genotype
groups.
S0/S0 (S/S, S/Lg, Lg/Lg) L0/L0 (La/La)
Female 11 11
Male 14 10
Age (M  SD) 20.4  3.5 20.3  2.5
BMI (M  SD) 19.4  3.0 19.2  1.7
Note: mean  standard deviation.
Abbreviation: BMI, Body Mass Index.
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Salivary cortisol was assessed using Salicaps (IBL Interna-
tional, Germany). Saliva samples were stored at 20 8C until
assayed at the laboratory of biopsychology at the University
of Dresden, Germany. Free cortisol concentrations in saliva
were measured using a commercially available ‘‘Lumines-
cence Immunoassay for the in vitro-diagnostic quantitative
determination of cortisol in human saliva and serum’’ (IBL,
Hamburg, Germany). The intra and interassay coefficients of
variance for cortisol was below 8%.
2.8. Design and procedure
This study was a randomised double-blind placebo-controlled
trial with stratification for genetic variation of the 5-HTTLPR
genotype. Participants were randomly allocated to receive 7
capsules containing either TRP (total dose of 2.8 g/day) or
placebo (cellulose microcrystalline) for a period of six days.
The dosage and duration were based on previous studies that
had shown social-behavioural effects of TRP administration
(3 g/day) after a period of 15 days (Aan het Rot et al., 2006)
and cognitive effects after a single dose of 0.8 g TRP (Markus
and Firk, 2009). The experimental procedure included two
visits to the laboratory, pre- and post-TRP.
2.9. First visit to laboratory
Upon arrival at the laboratory, participants provided written
informed consent for the study. Following the M.I.N.I. inter-
view, participants performed experimental tasks and filled
out questionnaires on a computer. At the end of the first visit,
participants were provided with 42 capsules that contained
400 mg tryptophan or placebo (PLC). Oral and written
instructions were provided to the participants regarding
the timing of administration of capsules and lifestyle restric-
tions during the next six days and on the day of the second lab
visit.
2.10. Tryptophan supplementation
Participants started to take the capsules the day after their
first lab visit. They were instructed to take two capsules in
the morning, two in the afternoon (before meals) and three in
the evening (before 23.00 h). Participants received a diary in
which they were asked to write down the exact time of intake
and number of capsules. Compliance was not measured
through blood sample analyses, however participants were
led to believe that compliance would be assessed at post-
intervention through a saliva sample.
Lifestyle instructions included: no smoking, no use of
dietary supplements and vitamins and consumption of alco-
hol limited to 3 units/day. Participants were also instructed
to refrain from alcohol and caffeine-containing consumptions
and avoid high carbohydrate meals on the day of their second
visit. Further instructions for the day of the second visit
included: no eating and drinking 1 h before arriving at the
laboratory (except water), and no physical exercise at least
2 h before arrival. Female participants were tested in the
luteal phase of their menstrual cycle. All test sessions started
in the afternoon between noon and 5 pm.2.11. Second visit to laboratory
Upon arrival at the lab participants handed in their diary
regarding the intake of capsules. In addition, they were asked
to fill out a debriefing questionnaire regarding compliance to
the instructions during the previous six days. They were also
interviewed about their compliance to the instructions for
the second lab visit. Next, participants were asked to per-
form a number of tests and to fill out questionnaires on a
computer. Finally, participants performed the TSST. After
completion of the TSST procedure participants were fully
debriefed and paid.
3. Results
3.1. Sample characteristics
For the total sample of n = 581, genotype frequencies were as
follows: SS, 16.9%; SLg, 4.8%; LgLg, 0.7%; LaLg, 8.6%; SLa,
43%; LaLa, 26%. Participants were divided on the basis of the
triallelic classification (Lg alleles were collapsed with S
variants into three genotype groups: S0/S0 (n = 130); L0/S0
(n = 300); L0/L0 (n = 151). Genotype frequencies were consis-
tent with Hardy—Weinberg equilibrium (x2 (1) = 0.67;
p = 0.41). We contacted 92 S0/S0 carriers and 92 L0/L0 carriers
by email. Sixty-four S0/S0 and 66 L0/L0 carriers expressed
interest in the study. After screening for in- and exclusion
criteria we included 26 S0/S0 and 22 L0/L0 participants. In each
group, one participant dropped out before day 2. Analyses
were conducted on 25 S0/S0 and 21 L0/L0 carriers.
The first two participants (one S0/S0 and one L0/L0 carrier)
received tryptophan single blind. Since the TSST panel was
double-blind for these participants and no observer ratings
were collected, we kept these participants in the analyses.
The demographic details of both groups are shown in Table 1.
Groups did not differ significantly on assessed demographic
characteristics. One participant in the PLC group (S0/S0 car-
rier) had a current diagnosis of panic disorder, and one
participant in the TRP group (S0/S0 carrier) had a specific
phobia (needles). Both participants were not taking any
medication.
3.2. Compliance
According to self-report, approximately 98% of the capsules
were taken according to instructions. The minimum percen-
tage of capsules taken by a participant was 69%. Three
participants had taken two capsules in the morning before
the second lab visit. All these participants were retained.
Figure 1 Salivary cortisol (nmol/l) before, during and after
exposure to social stress in S0/S0 group (A) and in L0/L0 group (B).
Table 2 Symptom scores for each genotype and intervention group assessed pre- and post-intervention.
Anxiety Depression Negative affect Positive affect
S0/S0 TRP Pre 3.6  2.0 1.9  1.2 12.1  4.3 30.1  6.7
Post 3.8  2.4 2.8  2.8 13.3  3.3 32.1  5.2
S0/S0 PLC Pre 4.8  3.3 1.4  1.6 12.8  2.8 32.6  4.0
Post 3.7  3.7 1.3  1.5 12.3  2.3 34.6  4.9
L0/L0 TRP Pre 3.8  2.4 1.4  1.4 12.2  2.7 30.3  8.5
Post 4.2  3.3 1.5  1.4 11.9  2.1 28.5  8.9
L0/L0 PLC Pre 3.9  3.8 2.4  2.6 13.1  2.4 29. 5  5.9
Post 3.7  2.2 2.5  2.3 15.4  7.0 31.9  8.2
Note: mean  standard deviation.
Abbreviations: TRP, tryptophan; PLC, placebo.
Tryptophan, stress and serotonin transporter gene 2053.3. Effects of TRP on psychiatric symptoms
In order to analyse the effects of intervention and genotype on
psychiatric symptoms, separate RM-GLMs for each of the ques-
tionnaire scores (HADS Anxiety, HADS Depression, PANAS-S Pos
and PANAS-S Neg) were conducted with Time as within subject
factor, and Intervention (TRP vs. PLC) and Genotype (S0/S0 vs. L0/
L0) as between subject factors. No significant effects were found
for intervention or genotype (Table 2).
3.4. Cortisol response to TSST
The cortisol data were not normally distributed. Log10-trans-
formations were successful in normalising the distributions.
Analyses of transformed data are reported, but the figures
represent untransformed data. RM-GLMs were conducted in
the S0/S0 and L0/L0 groups separately on cortisol concentra-
tions, with Time (the six cortisol measurements) as within
subjects factor and Intervention (TRP vs. PLC) as a between
subjects factor. Gender was included as covariate. Green-
house—Geisser statistics are reported. In the S0/S0 group, the
main effect of Time was significant (F(1.50, 33.07) = 6.72,
p = 0.007, hp2 = 0.234) and the time  intervention interac-
tion was borderline significant (F(1.50, 33.07) = 3.55,
p = 0.052, hp2 = 0.139). In the L0/L0 group, the main effect
of Time was a trend (F(1.76, 31.70) = 3.09, p = 0.065,
hp2 = 0.146) and the interaction was non-significant. Fig. 1
displays the cortisol concentrations over time by intervention
and genotype.
To further probe the time  intervention interaction
effect within the S0/S0 group, Independent-samples t-tests
were conducted, comparing cortisol concentrations at each
time point between TRP- and placebo-treated individuals.
Significant differences were observed at t65, t90 and t110.
Within the S0/S0 group, the TRP-treated participants differed
significantly from PLC-treated participants at t65
[t(19) = 2.73, p = 0.012, d = 1.11]. Significant differences
were also observed at t90 [t(23) = 2.27, p = 0.033, d = 0.92]
and at t110 [t(23) = 2.29, p = 0.031 d = 0.92].
3.5. Subjective mood response to TSST
A separate analysis was conducted for each scale of the MSS
questionnaire. RM-GLMs with time as within subjects factor,
Intervention and Genotype as between subjects factors andgender as covariate revealed a significant main effect of time
for the tension scale (F(2.78, 113.95) = 32.76, p < 0.01,
hp2 = 0.444), Anxiety scale (F(1.77, 72.59) = 11.23,
p < 0.01, hp2 = 0.215) and Annoyance scale (F(2.37,
97.24) = 4.46, p = 0.01, hp2 = 0.098). Tension, Anxiety and
Annoyance scores varied between 0 and 5; after reaching a
peak at t56 (after anticipation stress) and t65 (after speech
Figure 2 Mood state scores before, during and after exposure
to social stress across genotype and intervention group.
206 H. Cerit et al.and arithmetic task), the scores normalised to 0—1 at t90 and
t110 (rest) in all intervention and genotype groups. The
ratings of sadness remained between 0 and 1 at all time
points (F(2.16, 88.72) = 0.41, p = 0.68, hp2 = 0.010) (Fig. 2).
4. Discussion
Six days of TRP supplements attenuated the cortisol response
to stress in S0/S0 carriers of the serotonin transporter gene.
Following social stress, significantly lower cortisol concen-
trations were found in S0/S0 carriers treated with TRP than in
S0/S0 carriers treated with placebo. TRP had no effect in L0/L0
carriers, whose cortisol curves were comparable to TRP-
treated S0/S0 carriers. These effects of TRP on cortisol
response to stress were observed in the absence of any
effects on anxiety, depressive symptoms, or affect. Further-
more, neither genotype nor intervention had an effect on the
subjective mood response to the TSST.
Previous studies have found differential HPA axis activity
depending on 5-HTTLPR genotype (Gotlib et al., 2008; Alex-
ander et al., 2009; Wu¨st et al., 2009; Way and Taylor, 2010;
Mueller et al., 2010, 2011), but the effects of TRP supple-
ments on this association had not been investigated. Only one
study has investigated the effects of TRP (single dose, 0.8 g)
in S0/S0 vs. L0/L0 individuals (Markus and Firk, 2009), and found
no effect on the cortisol response to stress in either genotype
group. Notably, in this prior study the stressor failed to
produce a rise in cortisol. While the lack of a cortisol response
to stress in control conditions negated the opportunity to
observe a dampening of this effect, a small improvement of
mood was noted after 0.8 g TRP in S0/S0carriers but not in L0/L0
carriers.
In the present study, we found no effect of TRP on anxiety
and depression symptoms or mood states during exposure to
public speaking stress in either L0/L0 or S0/S0 carriers. While
the present findings seem to conflict with those of Markus and
Firk (2009), the latter utilised pooled mood states (pre- and
post-intervention) and also employed a crossover design. This
means that their participants were exposed to the same
stressor twice. Anticipation stress may have been different
during the second administration. Earlier studies, in which
genotype had not been assessed, found only small and rather
inconsistent effects of tryptophan loading on mood and stressresponse (Markus et al., 1998, 2000a,b, 2010; Merens et al.,
2005; Markus, 2007; Nesic and Duka, 2008; Firk and Markus,
2009). In contrast to the aforementioned studies, we pre-
selected our participants based on genotype, used a longer
intervention period of six days, and carefully selected parti-
cipants to eliminate potential confounders as much as pos-
sible (e.g. use of contraceptives, smoking).
Although the complex relationship between HPA axis
reactivity and 5-HTTLPR genotype remains to be further
elucidated, several studies have indicated that neurobiolo-
gical responses to negative or threatening stimuli are
mediated by 5-HTTLPR genotype. Healthy S carriers had
greater amygdala reactivity to negative facial expressions
(e.g., fearful and angry) than L/L carriers in a face-matching
task (Hariri et al., 2002, 2005). If 5-HTTLPR affects amygdala
response to negative environmental stimuli in general, this
may in turn also mediate HPA axis reactivity (Way and Taylor,
2009). At the molecular level the serotonin transporter
promoter polymorphism alters SLC6A4 transcription effi-
ciency and the level of serotonin transporter function (Lesch
et al., 1996; Greenberg et al., 1999). It remains unclear
exactly how the 5-HTT polymorphism alters neurochemical
processes between the pre- and post-synaptic cells. 5-
HTTLPR genotype-related alterations found so far include:
differential levels of extracellular 5-HT concentrations, dif-
ference in 5-HT clearance, changes in tissue 5-HT concentra-
tions, and 5-HT synthesis and turnover in the brain (as
reviewed by Murphy and Lesch, 2008). Since the short variant
is associated with reduced uptake or clearance of 5-HT as
compared with the long variant, it is also associated with
higher concentrations of 5-HT in the synaptic cleft. Conse-
quently, presynaptic 5HT1A autoreceptors may be oversti-
mulated in S carriers by the increased 5-HT concentrations.
The negative feedback mechanism of these autoreceptors
causes a decrease in 5-HT synthesis in the presynaptic cell,
reducing the amount of 5-HT in the synapse (Hoyer et al.,
1994). Subchronic administration of TRP might compensate
this process and result in an attenuated cortisol response to
social stress.
In summary, the 5-HTT polymorphism changes the
dynamic between post- and pre-synaptic cell and this may
also influence peripheral adrenomedullary and hypothalamo-
pituitary responses (Murphy and Lesch, 2008). As the precise
neurochemical differences between S0 and L0 carriers remain
unclear, the underlying mechanisms of our findings remain
speculative.
4.1. Limitations and future directions
Limitations of our study include the relatively small sample
size and the fact that we checked compliance only by self-
report and not by measuring TRP concentrations in plasma
before and after intervention. Self-reported compliance was
excellent. To optimise compliance, participants kept a diary
of the exact time of intake of capsules and had been led to
believe that compliance would be checked through a saliva
sample.
TRP supplementation of six days (2.8 g/day) may be used
in further studies as an experimental intervention to increase
TRP levels in 5-HT vulnerable populations (i.e. serotonergic
genotypes associated with stress vulnerability). In this study
we have shown that a group with a specific genotype seems to
Tryptophan, stress and serotonin transporter gene 207benefit more from TRP supplements, as TRP attenuated the
cortisol response to stress. Future studies may investigate
whether the same effects can also be reached with lower
dosages of TRP supplementation. Another essential ques-
tion that needs to be answered is the maximum duration of
the intervention. The daily requirement of tryptophan for
humans is between 3 and 5 mg/kg per day (World Health
Organization, 2002). We administered 2800 mg/day, which
is almost ten times this daily requirement. Although high
tryptophan intake has no serious adverse effects in animals
and humans (Garlick, 2004), the mechanism and safety of
long-term and high-dose TRP supplementation needs
further investigation (Le Floc’h et al., 2010). For instance,
cognitive dysfunctions have been observed after intrave-
nous TRP infusion in healthy first-degree relatives of
patients with bipolar disorder (Sobczak et al., 2003). In
‘quarrelsome’ individuals, however, a high dose of trypto-
phan (3 g/d) for 15 days decreased quarrelsome behaviours
and increased agreeableness (Aan het Rot et al., 2006).
Future studies may further investigate how the effects of
TRP supplements on the cognitive, physiological and beha-
vioural levels depend on serotonergic genotypes. Research
on TRP supplementation in individuals with serotonergic
genotypes conferring vulnerability to stress might give new
insights in personalised treatment of mood disorders.
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